You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

 

Online download statistics by month:

Online download statistics by month: October 2023 to September 2025

AbstractFullPdf
Oct 202316016153
Nov 2023517521291
Dec 2023218221161
Jan 2024160161117
Feb 202412412592
Mar 2024228232184
Apr 2024209210155
May 2024177180141
Jun 2024144144105
Jul 2024123124113
Aug 2024125122103
Sep 202414014096
Oct 2024191191127
Nov 2024185186121
Dec 202412212394
Jan 202515615696
Feb 202515115283
Mar 202513813895
Apr 2025133134102
May 202511111274
Jun 2025858571
Jul 2025110
Aug 2025110
Sep 2025110
Total360036212474